Media

Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients ALA-1000 is the first, three-month slow-release Buprenorphine injection. Initial results show a low initial burst without dose dumping effect, good safety, and tolerability. ALA-1000 has the potential to significantly increase compliance and reduce the risk of relapse in patients treated and stabilized with oral medications or other, shorter-interval Buprenorphine LAIs. TAICHUNG, March 9, 2021 /PRNewswire/ — Alar Pharmaceuticals Inc. (TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs) for central nervous system disorders, announces positive interim results from

Alar Pharmaceuticals Inc., a new drug development company focused on long-acting release drug products, has announced that it concluded its pre-Investigational New Drug (pre-IND) meeting with U.S. Food and Drug Administration (FDA) for ALA-3000 on August 21, 2020. ALA-3000 is a developing long-acting new drug to treat patients with treatment-resistant depression (TRD), which is designed with specific features to have safety benefits. In the written response, US FDA agrees with the development plans of Chemistry, Manufacturing, and Controls (CMC), nonclinical studies, and phase 1 clinical study for ALA-3000, and also provides feedback beyond the studies required for opening phase 1